Revised SPC: Olumiant (baricitinib) tablets

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
26 November 2019

Abstract

SPC now advises that if clinical features of DVT/PE occur, baricitinib should be discontinued and patients should be evaluated promptly, followed by appropriate treatment (previously the SPC warned that it should only be temporarily interrupted should VTE occur).